5 unchanged sentences
The high and low closing sales price of our common stock for the period from October 11, 2019 to December 31, 2020 was $75.00 and $11.65, respectively.
−Removed: On March 23, 2020, the closing sale price of our common stock was $36.61.
+Added: On February 22, 2021, the closing sale price of our common stock was $68.77.
Holders of Record
−Removed: As of March 23, 2020, there were approximately 282 stockholders of record of our common stock.
+Added: As of February 22, 2021, there were approximately 157 stockholders of record of our common stock.
The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees.
9 unchanged sentences
This graph shall not be deemed “soliciting material” or be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or the Securities Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
+Added: Biotechnology
Securities Authorized for Issuance Under Equity Compensation Plans
10 unchanged sentences
333-233604), which was declared effective on October 10, 2019.
−Removed: There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus filed with the SEC on October 11, 2019, pursuant to Rule 424(b)(4).
+Added: On July 10, 2020, we issued and sold 8,214,285 shares of our common stock pursuant to a Registration Statement on Form S-1 (File No.
+Added: 333-239689) and a registration statement on Form S-1 filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (File No.
+Added: 333-239747) (collectively, the “Registration Statements”).
+Added: The Registration Statements became effective on July 7, 2020.
+Added: The price of the shares sold in the follow-on offering was $42.00 per share and we received total gross proceeds from the offering of approximately $345.0 million.
+Added: After deducting underwriting discounts and commissions of $20.7 million and offering expenses of $1.1 million, the net proceeds were $323.2 million.
+Added: There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus filed with the SEC on October 11, 2019, pursuant to Rule 424(b)(4), and from our follow-on offering as described in our S-1 filed with the SEC on July 6, 2020, pursuant to Rule 462(b).
We invested the funds received in cash equivalents and other marketable securities in accordance with our investment policy.
Recent Sales of Unregistered Equity Securities
−Removed: In January 2019, we issued and sold an aggregate of 18,202,213 shares of Series B convertible preferred stock to 20 accredited investors at a purchase price per share of $18.00 for an aggregate purchase price of $327.5 million.
−Removed: The issuance and sale of these shares was deemed to be exempt from registration under Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D under the Securities Act as a transaction by an issuer not involving a public offering.
−Removed: Between January 1, 2019 and October 10, 2019, and pursuant to our 2016 Equity Incentive Plan, as amended, and 2019 Equity Incentive Plan, we granted stock options to purchase up to an aggregate of 2,637,734 shares of our common stock to our employees, consultants and directors at a weighted-average exercise price of $8.94 per share.
−Removed: The sales of these securities were deemed to be exempt from registration under Rule 701 under the Securities Act as transactions pursuant to compensatory benefit plans or contracts relating to compensation as provided under Rule 701, or under Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering.
Issuer Purchases of Equity Securities
3 unchanged sentences
The consolidated statement of operations data for each of the years ended December 31, 2020, 2019 and 2018 and the consolidated balance sheet data as of December 31, 2020 and 2019 are derived from our audited consolidated financial statements included elsewhere in this Form 10-K.
−Removed: The selected balance sheet data as of December 31, 2017 are derived from our audited consolidated financial statements which are not included in this Annual Report on Form 10-K.
−Removed: Our historical results of any prior periods are not necessarily indicative of results to be expected in any future period.
+Added: The selected consolidated statement of operations data for the year ended December 31, 2017 and consolidated balance sheet data as of December 31,
+Added: 2018 and 2017 are derived from our audited consolidated financial statements which are not included in this Annual Report on Form 10-K.
+Added: Our historical results of any prior periods are not necessar il y indicative of results to be expected in any future period.
Consolidated Statement of Operations Data:
2 unchanged sentences
Grant revenue
+Added: License revenue from a related party
Contract revenue
9 unchanged sentences
Total other income (expense)
−Removed: Loss before benefit from (provision for) income taxes
−Removed: Benefit from (provision for) income taxes
+Added: Loss before (provision for) benefit from income taxes
+Added: (Provision for) benefit from income taxes
Net loss per share, basic and diluted (1)
12 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.